Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

E-Prescribing’s Hurdle May Be DEA, Not Technology Or Physicians

Executive Summary

The Drug Enforcement Administration has pledged to issue rules permitting electronic prescribing of controlled substances, but neither the rules nor even a firm publication date appear forthcoming

You may also be interested in...



Restriction On Generic Drug Switches In DEA eRx Proposal Draws Criticism

A provision in the Drug Enforcement Administration's proposed rule for electronic prescribing of controlled substances that would prohibit pharmacists from substituting generic drugs for brand name drugs is drawing fire from various stakeholders

Restriction On Generic Drug Switches In DEA eRx Proposal Draws Criticism

A provision in the Drug Enforcement Administration's proposed rule for electronic prescribing of controlled substances that would prohibit pharmacists from substituting generic drugs for brand name drugs is drawing fire from various stakeholders

Part D’s Six Protected Drug Classes May Ride Baucus Medicare Vehicle

A statutory requirement that Medicare Part D drug plans cover "all or substantially all" drugs in six classes stands a good chance of making it into the Senate Finance Committee's upcoming Medicare physician payment package

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel